Explore 5-Amino-1MQ dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
5-Amino-1MQ is a small molecule NNMT inhibitor studied for its effects on metabolic health and fat cell differentiation. This data captures the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting this novel metabolic compound.
5-Amino-1-Methylquinolinium iodide (5-Amino-1MQ) is a small-molecule NNMT inhibitor developed out of the early structure-activity work on nicotinamide N-methyltransferase as a metabolic target. The mechanistic logic traces to a focused body of preclinical work on NNMT itself. NNMT is an intracellular enzyme that consumes nicotinamide as a methyl-acceptor substrate, producing 1-methylnicotinamide and depleting the nicotinamide pool that would otherwise be recycled into NAD+ via the salvage pathway. The Kraus et al. 2014 Nature paper ("Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity") established NNMT as a metabolic target by showing that genetic NNMT knockdown in mice reduced adiposity and improved insulin sensitivity on a high-fat diet, and the downstream small-molecule inhibitor work — most notably the Neelakantan et al.
5-Amino-1MQ is a small-molecule NNMT inhibitor (not a peptide) most often sourced for fat-loss and metabolic research, usually taken orally. It is commonly sold as capsules or powder and stocked alongside metabolic peptides.
NNMT methylates nicotinamide to 1-methylnicotinamide, consuming the methyl donor S-adenosylmethionine (SAM) and depleting the NAD+ salvage pool. Inhibiting NNMT with 5-Amino-1MQ is hypothesized to restore SAM and NAD+ pools, shift adipocyte energy balance toward expenditure, and reduce diet-induced obesity in animal models.
Pre-clinical work has reported reduced adipose-tissue mass, improved glucose homeostasis, and increased energy expenditure in diet-induced-obesity mouse models. No human clinical trials have been published. Research interest extends to skeletal-muscle aging and sarcopenia.
5-Amino-1MQ has a reported half-life of ~4 hours (estimated), and the dose intervals researchers model most often fall around once daily (oral). Short-acting, so a once-daily dose clears before the next with little buildup. Taking it at the same time each day keeps the effect steady. It is catalogued under Weight Loss on WPA.
1,047 5-Amino-1MQ reconstitution calculations have been logged by the WPA community. The most common dose entered is 1mg (306 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 50mg (600 sessions). The most common dosing frequency is daily (7x/week) (85 logged protocols), followed by once weekly (29).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.